Ren Yinlong, Hou Junna, Xu Aiguo, Pan Yunbao
Department of Pulmonary Medicine, The First Affiliated Hospital of Zhengzhou University Zhengzhou 450000, Henan, China.
Department of Pathology, Wuxi Medical School, Jiangnan UniversityWuxi 214122, Jiangsu, China; Department of Pathology, Affiliated Hospital, Jiangnan UniversityWuxi 214062, Jiangsu, China.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14709-16. eCollection 2015.
Lung cancer is the leading cause of cancer-related death in both men and women and consists of different histological types. Histopathological examination and accurate subtype diagnosis has become increasingly important in guiding patient management and, as such, is the most important currently available lung cancer "biomarker". In this study, we examined the expression of PAX2 and PAX5 by immunohistochemistry in 47 cases of lung cancer and 13 cases of pneumonia. The results demonstrated that PAX2 were detected in 82.8% (24/29) of NSCLC, 0% (0/18) of SCLC and 7.7% (1/13) of pneumonia, respectively; However, PAX5 were detected in 15/18 cases (83.3%) of SCLC, 6.8% (2/29) of NSCLC and 7.7% (1/13) of pneumonia. Further, the samples with lymphatic metastasis had remarkable higher positive PAX2 or PAX5 than that without metastases. Overall, our data indicated that PAX2 and PAX5 differentially expressed in NSCLC and SCLC. Thus, PAX2 and PAX5 are useful biomarker in the differential diagnosis of lung cancer.
肺癌是男性和女性癌症相关死亡的主要原因，由不同的组织学类型组成。组织病理学检查和准确的亚型诊断在指导患者管理方面变得越来越重要，因此，它是目前最重要的肺癌“生物标志物”。在本研究中，我们通过免疫组织化学检测了47例肺癌和13例肺炎中PAX2和PAX5的表达。结果表明，PAX2分别在82.8%（24/29）的非小细胞肺癌、0%（0/18）的小细胞肺癌和7.7%（1/13）的肺炎中被检测到；然而，PAX5在18例小细胞肺癌中的15例（83.3%）、29例非小细胞肺癌中的2例（6.8%）和13例肺炎中的1例（7.7%）中被检测到。此外，有淋巴转移的样本中PAX2或PAX5的阳性率明显高于无转移的样本。总体而言，我们的数据表明PAX2和PAX5在非小细胞肺癌和小细胞肺癌中差异表达。因此，PAX2和PAX5是肺癌鉴别诊断中有用的生物标志物。
